AU2007248112A1 - Use of organic compounds - Google Patents

Use of organic compounds Download PDF

Info

Publication number
AU2007248112A1
AU2007248112A1 AU2007248112A AU2007248112A AU2007248112A1 AU 2007248112 A1 AU2007248112 A1 AU 2007248112A1 AU 2007248112 A AU2007248112 A AU 2007248112A AU 2007248112 A AU2007248112 A AU 2007248112A AU 2007248112 A1 AU2007248112 A1 AU 2007248112A1
Authority
AU
Australia
Prior art keywords
disease
diabetes
treatment
erry
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007248112A
Other languages
English (en)
Inventor
Shamina M. Rangwala
Susan C. Stevenson
Zhidan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38477124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007248112(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2007248112A1 publication Critical patent/AU2007248112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2007248112A 2006-05-03 2007-05-02 Use of organic compounds Abandoned AU2007248112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79722806P 2006-05-03 2006-05-03
US60/797,228 2006-05-03
PCT/US2007/067971 WO2007131005A2 (en) 2006-05-03 2007-05-02 Use of organic compounds

Publications (1)

Publication Number Publication Date
AU2007248112A1 true AU2007248112A1 (en) 2007-11-15

Family

ID=38477124

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007248112A Abandoned AU2007248112A1 (en) 2006-05-03 2007-05-02 Use of organic compounds

Country Status (13)

Country Link
US (1) US20090281191A1 (https=)
EP (1) EP2015777B1 (https=)
JP (1) JP2009535425A (https=)
KR (1) KR20090005137A (https=)
CN (1) CN101432024A (https=)
AT (1) ATE477819T1 (https=)
AU (1) AU2007248112A1 (https=)
BR (1) BRPI0711174A2 (https=)
CA (1) CA2649701A1 (https=)
DE (1) DE602007008553D1 (https=)
MX (1) MX2008014008A (https=)
RU (1) RU2008147269A (https=)
WO (1) WO2007131005A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
US8962546B2 (en) * 2011-03-01 2015-02-24 Salk Institute For Biological Studies Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP3010587A4 (en) * 2013-06-18 2017-04-12 Salk Institute for Biological Studies Methods of treating muscular dystrophy
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
BR112016017045A2 (pt) 2014-01-31 2017-08-08 Dana Farber Cancer Inst Inc Derivados de diazepano e usos dos mesmos
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
EP3739041A1 (en) 2014-03-27 2020-11-18 The Salk Institute for Biological Studies Compositions and methods for treating type 1 and type 2 diabetes and related disorders
KR20170032474A (ko) * 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
AU2016225076B2 (en) 2015-02-27 2018-09-13 Salk Institute For Biological Studies Reprogramming progenitor compositions and methods of use therefore
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
WO2017053084A1 (en) * 2015-09-25 2017-03-30 Salk Institute For Biological Studies Estrogen related receptor gamma (erry) enhances and maintains brown fat thermogenic capacity
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2017269364B2 (en) 2016-05-25 2023-08-31 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466415C (en) * 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., a novel pgc-1 homologue and uses therefor
WO2004015415A1 (ja) * 2002-08-08 2004-02-19 Japan Science And Technology Agency 薬剤スクリーニング方法
US20050074765A1 (en) * 2002-10-16 2005-04-07 Blanchard Steven G. Methods for identifying and using modulators of estrogen related receptor gamma
WO2006130503A2 (en) * 2005-05-27 2006-12-07 Janssen Pharmaceutica N.V. Errϝ peptide fragment complexes and uses thereof in drug discovery

Also Published As

Publication number Publication date
EP2015777A2 (en) 2009-01-21
US20090281191A1 (en) 2009-11-12
WO2007131005A3 (en) 2008-06-19
MX2008014008A (es) 2009-03-25
BRPI0711174A2 (pt) 2011-08-23
JP2009535425A (ja) 2009-10-01
DE602007008553D1 (de) 2010-09-30
WO2007131005A2 (en) 2007-11-15
CA2649701A1 (en) 2007-11-15
RU2008147269A (ru) 2010-06-10
KR20090005137A (ko) 2009-01-12
EP2015777B1 (en) 2010-08-18
ATE477819T1 (de) 2010-09-15
CN101432024A (zh) 2009-05-13

Similar Documents

Publication Publication Date Title
US20090281191A1 (en) Use of organic compounds
Ribas et al. Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females
Clayton et al. Cellular senescence contributes to large elastic artery stiffening and endothelial dysfunction with aging: amelioration with senolytic treatment
Zhou et al. Melatonin inhibits glucose-induced apoptosis in osteoblastic cell line through PERK-eIF2α-ATF4 pathway
Su et al. N-acetylcysteine attenuates myocardial dysfunction and postischemic injury by restoring caveolin-3/eNOS signaling in diabetic rats
Li et al. Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling
Consitt et al. Peroxisome proliferator–activated receptor-γ coactivator-1α overexpression increases lipid oxidation in myocytes from extremely obese individuals
Brown et al. The APOE4 genotype alters the response of microglia and macrophages to 17β-estradiol
Ding et al. Insulin resistance disrupts the interaction between AKT and the NMDA receptor and the inactivation of the CaMKIV/CREB pathway in minimal hepatic encephalopathy
Tanis et al. The effect of glucose concentration and sodium phenylbutyrate treatment on mitochondrial bioenergetics and ER stress in 3T3-L1 adipocytes
Sesti et al. Low circulating insulin-like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult subjects
Xiao et al. Mitochondrial energetic impairment in a patient with late‐onset glutaric acidemia Type 2
Ghosh et al. Churchill's Pocketbook of Diabetes E-Book
JP2005523004A (ja) グルコース取り込みの増加及びｉｉ型糖尿病の治療のためのｎａｄ（ｐ）ｈオキシダーゼ阻害剤
JP5901770B2 (ja) Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
WO2024030909A1 (en) Biomarkers of amino acid composition treatment response in long covid
Gao et al. Oxidative stress increases the risk of pancreatic β cell damage in chronic renal hypertensive rats
CN1720051A (zh) 脂肪调节
WO2010007085A2 (en) Use of organic compounds
Maculewicz et al. Association between peroxisome proliferator-activated receptor-alpha,-delta and-gamma gene (PPARA, PPARD, PPARG) polymorphisms and overweight parameters in physically active men
US10292980B2 (en) GAPDH cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness
US10376484B2 (en) Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction
Katte et al. Atypical diabetes subtypes in Black African populations
WO2005085846A1 (ja) 虚血性心疾患危険群診断薬
Ahmed Alelyan et al. ASSESSMENT OF SERUM OMENTIN-1 HORMONE, FERRITIN AND LIPID PROFILE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted